Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	28219
Country	United Kingdom

Received	2016-06-29 09:55
Peer-Review Started	2016-06-29 14:49
To Make the First Decision	2016-08-26 08:16
Return for Revision	2016-08-29 17:02
Revised	2016-10-13 05:42
Second Decision	2016-11-10 14:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-11-22 15:23
Articles in Press	2016-11-22 15:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-28 20:29
Publish the Manuscript Online	2017-01-12 12:07

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
Manuscript Source	Invited Manuscript
All Author List	Esther Una Cidon
Funding Agency and Grant Number
Corresponding Author	Esther Una Cidon, MD, PhD, Medical Oncologist, Department of Medical Oncology, Royal Bournemouth Hospital, Castle Lane East, Castle Ln E, Bournemouth BH5 2AZ, United Kingdom. aunacid@hotmail.com
Key Words	Gastroenteropancreatic neuroendocrine tumors; Peptide receptor radionuclide therapy; Soma­tostatin analogs; Octreotide; Transarterial chemoemboli­zation; Carcinoid syndrome; Setotonin; Chromogranin
Core Tip	The management of localized NETs is straight forward, however, the treatment of advanced tumors involves several disciplines and requires a coordinated multidisciplinary approach. Recent advances in molecular biology have expanded the therapeutic arsenal. Somatostatin analogs, initially approved for control of hormonal syndromes, have recently proven to inhibit tumor growth. Several new drugs, antiangiogenics, mTOR inhibitors have been tested with promising results and some of them have already been approved. Several trials are still under way but the future should focus on patient selection, predictive markers, and tolerability improvement as critical aspects to continue advancing.
Publish Date	2017-01-12 12:07
Citation	Una Cidon E. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20
URL	http://www.wjgnet.com/1948-5204/full/v9/i1/4.htm
DOI	http://dx.doi.org/10.4251/wjgo.v9.i1.4

Full Article (PDF)	WJGO-9-4.pdf
Full Article (Word)	WJGO-9-4.doc
Manuscript File	28219-Review.docx
Answering Reviewers	28219-Answering reviewers.pdf
Audio Core Tip	28219-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	28219-Conflict-of-interest statement.pdf
Copyright License Agreement	28219-Copyright assignment.pdf
Peer-review Report	28219-Peer-review(s).pdf
Scientific Misconduct Check	28219-Scientific misconduct check.pdf
Scientific Editor Work List	28219-Scientific editor work list.pdf